Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Replimune Group Inc REPL

Healthcare Biotechnology
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a... see more

Recent & Breaking News (NDAQ:REPL)

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswire November 2, 2022

Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

GlobeNewswire October 7, 2022

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

GlobeNewswire August 4, 2022

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswire August 1, 2022

Replimune Announces the Departure of Jason Rhodes from its Board of Directors

GlobeNewswire June 3, 2022

Replimune to Present at the Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 26, 2022

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 19, 2022

Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies

GlobeNewswire March 30, 2022

Replimune to Host Virtual Investor Event on March 30, 2022

GlobeNewswire March 21, 2022

Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 11, 2022

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

GlobeNewswire February 3, 2022

Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

GlobeNewswire January 31, 2022

Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones

GlobeNewswire January 10, 2022

Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2022

Replimune Appoints Christy Oliger to its Board of Directors

GlobeNewswire December 2, 2021

Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

GlobeNewswire November 12, 2021

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 4, 2021

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswire November 1, 2021

Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

GlobeNewswire October 1, 2021